Buturović-Ponikvar Jadranka
Department of Nephrology, University Medical Center Ljubljana, Ljubljana, Slovenia.
Ther Apher Dial. 2005 Jun;9(3):196-201. doi: 10.1111/j.1774-9987.2005.00252.x.
The total number of end-stage renal disease patients treated by renal replacement therapy increased from 1584 on 31 December 2002 to 1661 on 31 December 2003 (4.9% increase). Of these patients, 70.5% were treated by hemodialysis, 7.0% by peritoneal dialysis and 22.5% had a functioning renal graft. The patients were treated at 18 dialysis centers and one transplant center. The number of prevalent patients treated by renal replacement therapy per million of the population (p.m.p.) was 846 at the end of 2003. The number of incident (new) patients in 2003 was 131 p.m.p. The gross mortality rate of dialysis patients was stable through the years of the study and reached 11.8% in 2003. 57.6% of new patients starting hemodialysis were > or = 65 years old and 23.2% were diabetics. Epoetin therapy was prescribed to 89.8% of dialysis patients. The number of patients positive for hepatitis B or hepatitis C viruses is stable and low (3.1% of all dialysis patients).
接受肾脏替代治疗的终末期肾病患者总数从2002年12月31日的1584例增加至2003年12月31日的1661例（增长4.9%）。在这些患者中，70.5%接受血液透析治疗，7.0%接受腹膜透析治疗，22.5%拥有功能正常的肾移植。患者在18个透析中心和1个移植中心接受治疗。2003年末每百万人口中接受肾脏替代治疗的现患患者数为846例。2003年的新发病例数为每百万人口131例。透析患者的总死亡率在研究期间保持稳定，2003年达到11.8%。开始接受血液透析的新患者中，57.6%年龄≥65岁，23.2%为糖尿病患者。89.8%的透析患者接受促红细胞生成素治疗。乙肝或丙肝病毒检测呈阳性的患者数量稳定且较少（占所有透析患者的3.1%）。
